Company information
- Ticker
- PSYCF
- Country
- United States
- Sector
- Consumer Staples
- Industry
- Food
Psyched Wellness Business Summary
Psyched Wellness Ltd. (PSYCF) operates as a health supplements company focused on the production and distribution of consumer packaged goods (CPG) derived from the Amanita Muscaria mushroom. The company generates revenue primarily through direct-to-consumer (DTC) transactions via its e-commerce platform and wholesale distribution through retail partnerships, including United Natural Foods (UNFI) and specialty retailers like Harmons. Its business segments are centered on its proprietary AME-1 extract, marketed through product lines such as "Calm" (tinctures), "Calmer" (double-strength relaxation formula), and "Santa" (dietary supplement shots). Positioned as a pioneer in the legal Amanita Muscaria market, Psyched Wellness differentiates itself by focusing on non-psilocybin, muscimol-based wellness rather than clinical psychedelic therapy. Its primary competitors include Cybin Inc., Compass Pathways plc, and Revive Therapeutics Ltd., though Psyched Wellness occupies a unique niche in the functional mushroom CPG space compared to the drug-development focus of its peers. The leadership team is led by CEO and Director Jeffrey Stevens, who brings over 20 years of capital markets experience and a track record of taking multiple companies public. Operations are managed by COO David Shisel, an experienced entrepreneur with a background in international business and legal compliance, while Kyle Nazareth serves as Chief Financial Officer, overseeing financial strategy following his appointment in mid-2024. The company’s scientific and strategic direction is bolstered by a high-profile board and advisory team, including Director Professor David Nutt, a world-renowned neuropsychopharmacologist and former chair of the Advisory Council on the Misuse of Drugs, and Director Michael Nederhoff, the former President of Juul Labs Canada. Notable institutional presence includes the company's inclusion in the AdvisorShares Psychedelics ETF (PSYK), reflecting its standing within the emerging life sciences sector.